Project Grant R01CA287279
Award Date
4/1/25
Completion Date
3/31/30
Dollars Obligated
$695K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This $449,196 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the University of Texas Southwestern Medical Center to investigate mechanisms of therapeutic resistance in cancer. The research focuses on elucidating how inhibition of receptor tyrosine kinases (RTKs), a common targeted cancer therapy approach, can trigger adaptive responses in cancer cells that lead to secondary resistance. Specifically, the project will...
This $670,358 federal Project Grant award was made by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to The University of Texas MD Anderson Cancer Center. The funding supports research to dissect the role of B lineage cells in mediating the response of resectable lung cancer to neoadjuvant immune-based therapy. The key objectives are to determine the transcriptional, immunogenomic, and spatial landscapes of B lineage cells in human non-small cell...
This $450,429 Project Grant award from the National Cancer Institute (NCI), part of the National Institutes of Health, supports research to advance immunotherapy for non-small cell lung cancer (NSCLC) by targeting the MUC1-C protein. The goal is to identify novel therapeutic strategies using anti-MUC1-C antibody-drug conjugates (ADCs) alone and in combination with immune checkpoint inhibitors (ICIs) to enhance anti-tumor immunity and restrain NSCLC progression, particularly for EGFR-mutant...
This federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $613,125.00 to The University of Texas MD Anderson Cancer Center to develop EGFRXHER3 bispecific CAR-T cells for targeting EGFR tyrosine kinase inhibitor drug-tolerant persister cells. The award, effective February 1, 2025 through January 31, 2028, supports research aimed at improving treatments for cancer patients. As a prominent research institution, MD...
This $762,992 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by the University of Texas MD Anderson Cancer Center to map and predict therapy resistance in small cell lung cancer (SCLC) using liquid biopsies. The 3-year award, effective July 1, 2024, will enable MD Anderson to conduct personalized analyses to better understand how SCLC tumors evolve and become resistant to treatment. This work aims to...
This Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) provides $279,465 to the University of Colorado-Denver to support research aimed at understanding how the tumor microenvironment impacts response to tyrosine kinase inhibitor (TKI) therapies in patients with ALK-positive non-small cell lung cancer (NSCLC). The key focus is determining how neutrophils recruited to the tumor microenvironment impair anti-tumor CD8+ T cell activity and...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) will support research by the University of Texas MD Anderson Cancer Center to investigate mechanisms of resistance to KRAS G12C inhibitors in SMARCA4-mutant lung cancer. The $267,527 award, effective January 1, 2025 through December 31, 2026, will fund experiments to: 1) determine how SMARCA4 mutations confer resistance to KRAS G12C inhibitors, 2) develop SMARCA2 degrader compounds to...
This Project Grant award from the National Cancer Institute (NCI), under the Federal Grant Program for Cancer Treatment Research (CFDA 93.395), provides $503,685 to Virginia Commonwealth University (VCU) to evaluate a new agent, PEPDG278D, for overcoming drug resistance in non-small cell lung cancer (NSCLC).
The key objectives are to: 1) assess PEPDG278D for inhibiting oncogenic signaling and antitumor activity in NSCLC cells and tumors expressing wild-type EGFR, and compare it to the...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research (CFDA 93.395) program is providing $531,379 to the University of California, Los Angeles (UCLA) to investigate mitochondrial networks as a critical determinant of response to antibody drug conjugates (ADCs) in advanced/metastatic non-small cell lung cancer (NSCLC). The goal is to evaluate how the structure and function of tumor mitochondrial networks impact the efficacy of three...
The National Cancer Institute (NCI) has awarded a $680,507 Project Grant under the Cancer Treatment Research Program (CFDA 93.395) to The Regents of the University of California, San Francisco (UCSF). The grant, awarded on April 1, 2025, will fund a 5-year research project to elucidate the mechanisms of cancer persister cell formation and identify druggable targets to eliminate these therapy-resistant cell populations in KRAS-mutant non-small cell lung cancer. The key objectives are to: (1)...